Skip to main content

Advertisement

SpringerLink
Log in

Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

The prognosis of scirrhous gastric carcinoma (SGC), which is characterized by rapid infiltration and proliferation of cancer cells accompanied by extensive stromal fibrosis, is extremely poor. In this study, we report the establishment of a unique SGC cell line from a gastric cancer patient in whom an autopsy was performed.

Methods

A new SGC cell line, OCUM-14, was established from malignant ascites of a male patient with SGC. A postmortem autopsy was performed on the patient. Characterization of OCUM-14 cells was analyzed by microscopic examination, reverse transcription polymerase chain reaction, fluorescence in situ hybridization analysis, immunohistochemical examination, CCK-8 assay, and in vivo assay.

Results

OCUM-14 cells grew singly or in clusters, and were floating and round-shaped. Most OCUM-14 cells had many microvilli on their surfaces. The doubling time was 43.1 h, and the subcutaneous inoculation of 1.0 × 107 OCUM-14 cells into mice resulted in 50% tumor formation. mRNA expressions of fibroblast growth factor receptor 2 (FGFR2) and human epidermal growth factor receptor 2 (HER2) were observed in OCUM-14 cells. FGFR2, but not HER2, overexpression was found in OCUM-14 cells. The heterogeneous overexpression of FGFR2 was also found in both the primary tumor and metastatic lesions of the peritoneum, lymph node, bone marrow, and lung of the patient. The FGFR2 inhibitors AZD4547 and BGJ398 significantly decreased the growth of OCUM-14 cells, while paclitaxel and 5-fluorouracil significantly decreased the proliferation of OCUM-14 cells, but cisplatin did not.

Conclusion

A new gastric cancer cell line, OCUM-14, was established from SGC and showed FGFR2 overexpression. OCUM-14 might be useful for elucidating the characteristic mechanisms of SGC and clarifying the effect of FGFR2 inhibitors on SGC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    Article  PubMed  Google Scholar 

  2. Yashiro M, Chung YS, Kubo T, Hato F, Sowa M. Differential responses of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. Br J Cancer. 1996;74(7):1096–103.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Otsuji E, Kuriu Y, Okamoto K, et al. Outcome of surgical treatment for patients with scirrhous carcinoma of the stomach. Am J Surg. 2004;188(3):327–32.

    Article  PubMed  Google Scholar 

  4. Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16(1):1–27.

    Article  PubMed  Google Scholar 

  5. Yashiro M, Matsuoka T, Ohira M. The significance of scirrhous gastric cancer cell lines: the molecular characterization using cell lines and mouse models. Hum Cell. Epub 6 Jun 2018. https://doi.org/10.1007/s13577-018-0211-4.

  6. Grygielewicz P, Dymek B, Bujak A, et al. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells. Gastric Cancer. 2016;19(1):53–62.

    Article  PubMed  CAS  Google Scholar 

  7. Matsumoto K, Arao T, Hamaguchi T, et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer. 2012;106(4):727–32.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Papadopoulos KP, El-Rayes BF, Tolcher AW, et al. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br J Cancer. 2017;117(11):1592–9.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Porta C, Giglione P, Liguigli W, Paglino C. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Fut Oncol. 2015;11(1):39–50.

    Article  PubMed  CAS  Google Scholar 

  10. Angevin E, Lopez-Martin JA, Lin CC, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013;19(5):1257–68.

    Article  PubMed  CAS  Google Scholar 

  11. Van Cutsem E, Bang YJ, Mansoor W, et al. A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017;28(6):1316–24.

    Article  PubMed  Google Scholar 

  12. Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–82.

    Article  PubMed  CAS  Google Scholar 

  13. Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015;33(30):3401–8.

    Article  PubMed  CAS  Google Scholar 

  14. Michael M, Bang YJ, Park YS, et al. A phase 1 study of LY2874455, an oral selective pan-FGFR inhibitor, in patients with advanced cancer. Target Oncol. 2017;12(4):463–74.

    Article  PubMed  Google Scholar 

  15. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18(7):1855–62.

    Article  PubMed  CAS  Google Scholar 

  16. Kunii K, Davis L, Gorenstein J, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008;68(7):2340–8.

    Article  PubMed  CAS  Google Scholar 

  17. Nakamura K, Yashiro M, Matsuoka T, et al. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology. 2006;131(5):1530–41.

    Article  PubMed  CAS  Google Scholar 

  18. Hattori Y, Odagiri H, Nakatani H, et al. K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc. Natl. Acad. Sci. USA. 1990;87(15):5983–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  19. Jung K, Park MI, Kim SE, Park SJ. Borrmann type 4 advanced gastric cancer: focus on the development of scirrhous gastric cancer. Clin Endosc. 2016;49(4):336–45.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Seabright M. A rapid banding technique for human chromosomes. Lancet. 1971;2(7731):971–2.

    Article  PubMed  CAS  Google Scholar 

  21. Capes-Davis A, Reid YA, Kline MC, et al. Match criteria for human cell line authentication: where do we draw the line? Int. J. Cancer. 2013;132(11):2510–9.

    Article  PubMed  CAS  Google Scholar 

  22. Yashiro M, Shinto O, Nakamura K, et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int. J. Cancer. 2010;126(4):1004–16.

    PubMed  CAS  Google Scholar 

  23. Xie L, Su X, Zhang L, et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 2013;19(9):2572–83.

    Article  PubMed  CAS  Google Scholar 

  24. Saka H, Kitagawa C, Kogure Y, et al. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. Investig New Drugs. 2017;35(4):451–62.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Guagnano V, Furet P, Spanka C, et al. Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 2011;54(20):7066–83.

    Article  PubMed  CAS  Google Scholar 

  26. MacLeod RA, Dirks WG, Matsuo Y, Kaufmann M, Milch H, Drexler HG. Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer. 1999;83(4):555–63.

    Article  PubMed  CAS  Google Scholar 

  27. Nakazawa K, Yashiro M, Hirakawa K. Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res. 2003;63(24):8848–52.

    PubMed  CAS  Google Scholar 

  28. Liu YJ, Shen D, Yin X, et al. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. Br J Cancer. 2014;110(5):1169–78.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Toyokawa T, Yashiro M, Hirakawa K. Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol Rep. 2009;21(4):875–80.

    PubMed  Google Scholar 

  30. Hattori Y, Itoh H, Uchino S, et al. Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res. 1996;2(8):1373–81.

    PubMed  CAS  Google Scholar 

  31. Yashiro M, Hirakawa K. Cancer-stromal interactions in scirrhous gastric carcinoma. Cancer Microenviron. 2010;3(1):127–35.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  32. Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34(2):280–300.

    Article  PubMed  CAS  Google Scholar 

  33. Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72(8):2045–56.

    Article  PubMed  CAS  Google Scholar 

  34. Noda S, Yashiro M, Toyokawa T, et al. Borrmann’s macroscopic criteria and p-Smad2 expression are useful predictive prognostic markers for cytology-positive gastric cancer patients without overt peritoneal metastasis. Ann Surg Oncol. 2011;18(13):3718–25.

    Article  PubMed  Google Scholar 

  35. Oono Y, Kuwata T, Takashima K, et al. Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. Surg Endosc. 2018;32(9):3964–71.

    Article  PubMed  Google Scholar 

  36. Fuyuhiro Y, Yashiro M, Noda S, et al. Myofibroblasts are associated with the progression of scirrhous gastric carcinoma. Exp Ther Med. 2010;1(4):547–51.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Kasashima H, Yashiro M, Nakamae H, et al. CXCL1-chemokine (C-X-C Motif) receptor 2 signaling stimulates the recruitment of bone marrow-derived mesenchymal cells into diffuse-type gastric cancer stroma. Am J Pathol. 2016;186(11):3028–39.

    Article  PubMed  CAS  Google Scholar 

  38. Fuyuhiro Y, Yashiro M, Noda S, et al. Upregulation of cancer-associated myofibroblasts by TGF-beta from scirrhous gastric carcinoma cells. Br J Cancer. 2011;105(7):996–1001.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  39. Fuyuhiro Y, Yashiro M, Noda S, et al. Cancer-associated orthotopic myofibroblasts stimulates the motility of gastric carcinoma cells. Cancer Sci. 2012;103(4):797–805.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Kayo Tsubota (Osaka City University Graduate School of Medicine) and Hideki Nakagawa (Research support platform of Osaka City University Graduate School of Medicine) for technical assistance. This study was partially supported by JSPS KAKENHI (Grant-in-Aid for Scientific Research B; Grant Nos. JP23390329, JP18H02883), and the Strategic Research Fund of Osaka City University.

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka City, Osaka, Japan

    Tomohisa Okuno MD, Masakazu Yashiro MD, PhD, Go Masuda MD, PhD, Shingo Togano MD, Kenji Kuroda MD, Yuichiro Miki MD, PhD, Kosei Hirakawa MD, PhD & Masaichi Ohira MD, PhD

  2. Molecular Oncology and Therapeutics, Osaka City University Graduate School of Medicine, Osaka City, Japan

    Tomohisa Okuno MD, Masakazu Yashiro MD, PhD, Shingo Togano MD, Kenji Kuroda MD & Yuichiro Miki MD, PhD

  3. Cancer Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka City, Japan

    Tomohisa Okuno MD, Masakazu Yashiro MD, PhD, Shingo Togano MD, Kenji Kuroda MD & Yuichiro Miki MD, PhD

  4. Department of Diagnostic Pathology, Osaka City University Graduate School of Medicine, Osaka City, Japan

    Masahiko Ohsawa MD, PhD

  5. Molecular Pathology, Osaka City University Graduate School of Medicine, Osaka City, Japan

    Hideki Wanibuchi MD, PhD

Authors
  1. Tomohisa Okuno MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masakazu Yashiro MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Go Masuda MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shingo Togano MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kenji Kuroda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuichiro Miki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kosei Hirakawa MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masahiko Ohsawa MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hideki Wanibuchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Masaichi Ohira MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study concept and design: MY; material collection: GM, MO, and MY; data acquisition: YM, TO, KK, GM; analysis and interpretation of data: YM, and MY; drafting of the manuscript: YM and MY; and study supervision: MY, MO, KH, and MO.

Corresponding author

Correspondence to Masakazu Yashiro MD, PhD.

Ethics declarations

Disclosure

There are no financial or other interests with regard to the submitted manuscript that might be construed as a conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Fig. S1

Growth curve of OCUM-14 cells. The doubling time of OCUM-14 cells was 43.1 h (TIFF 54 kb)

Fig. S2

STR profile of OCUM-14. OCUM-14 was matched in < 80% of alleles for 16 loci (TIFF 227 kb)

Fig. S3

Effect of trastuzumab on the growth of OCUM-14. The proliferation of OCUM-14 cells was not inhibited by trastuzumab (TIFF 55 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okuno, T., Yashiro, M., Masuda, G. et al. Establishment of a New Scirrhous Gastric Cancer Cell Line with FGFR2 Overexpression, OCUM-14. Ann Surg Oncol 26, 1093–1102 (2019). https://doi.org/10.1245/s10434-018-07145-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-018-07145-2

Search

Navigation